Lakefront Biotherapeutics N.V.

LKFT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$28.80

+$0.53 · +1.87%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

65/100

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

Deep Value

Momentum

Neutral

Sentiment

Mixed

Risk resilience

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

Industry: Biotechnology
Sector: Healthcare
Headquarters: BE
CEO: Henry O. Gosebruch
Listed since: May 5, 2005
Employees: 452

Market position

Day range

Current $28.80

$28.27$28.83

52-week range

Current $28.80

$25.68$37.78

Open: $28.27
Previous close: $28.27
Volume: 264.38K; 1.4× average
Average volume: 189.49K; Average daily volume
Market cap: 1.9B USD
Beta: 0.12; Market reference 1
50-day average: $28.6518; +0.52% above average
200-day average: $30.5096; -5.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.75B EUR
EV / EBITDA: 4.88×
Earnings yield: 17.50%
Free cash flow yield: -14.79%

Profitability & efficiency

Return on equity: 9.92%
Return on assets: 9.42%
Return on invested capital: 15.40%

Financial health

Current ratio: 20.15×

Financial statements

Metric (EUR)	FY2025
Revenue	1.11B EUR
Cost of goods sold	29.74M EUR
Gross profit	1.08B EUR
Research and development	459.42M EUR
Selling, general, and administrative	111.96M EUR
Operating expenses	581.12M EUR
Interest income	46.34M EUR
Interest expense	2.22M EUR
Depreciation and amortization	55.88M EUR
Operating income	501.39M EUR
Net income	320.88M EUR